PION PION 深 滬
等待開盤 07-06 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 0
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Airbus And Leonardo Call For European Space Champion To Take On Spacex- FT
BRIEF-Airbus And Leonardo Call For European Space Champion To Take On Spacex- FT June 23 (Reuters) - AIRBUS AND LEONARDO CALL FOR EUROPEAN SPACE CHAMPION TO TAKE ON SPACEX- FT Source https://tinyurl.com/627ynr2p (( Reuters.Briefs@thomsonreuters.com ;))
06-23 18:21
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Oculis Holding AG will present at Clinical Trials at the Summit 2026 in Las Vegas, discussing Privosegtor, a novel neuroprotective therapy for optic neuritis (ON). Privosegtor, a peptoid small molecule, can cross both the blood-brain and retinal barriers, targeting unmet needs in ON and other optic neuropathies. The company has achieved significant milestones, including Breakthrough Therapy designation from the FDA and PRIME designation from the ...
06-11 08:00
Motor racing-McLaren join Ferrari as only F1 teams to make 1,000 GP starts
Motor racing-McLaren join Ferrari as only F1 teams to make 1,000 GP starts Monaco will officially be McLaren's 1,000th F1 start Team have won 10 constructors' and 13 drivers' titles, 203 grands prix Ferrari celebrated their milestone in 2020 By Alan Baldwin LONDON, June 1 (Reuters) - Bruce McLaren,
06-01 14:00
BRIEF-Luffa Secures Strategic Investment From Gofintech Quantum At US$220 Million Valuation
BRIEF-Luffa Secures Strategic Investment From Gofintech Quantum At US$220 Million Valuation May 26 (Reuters) - LUFFA SECURES STRATEGIC INVESTMENT FROM GOFINTECH QUANTUM AT US$220 MILLION VALUATION, PIONEERING AI + FINTECH FRONTIER Source text: ID:nGNX66p4MR (( Reuters.Briefs@thomsonreuters.com ;))
05-26 21:47
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Oculis Holding AG will present updates on its late-stage pipeline and key unmet medical needs in ophthalmology at the ARVO 2026 Annual Meeting. Highlights include findings from the DME AWARE Delphi Study emphasizing the need for non-invasive therapies for diabetic macular edema (DME), post-hoc analysis of Privosegtor's impact on retinal ganglion cell loss in optic neuritis, and a corporate update on upcoming milestones. The company is advancing O...
05-01 08:00
Boston Scientific says CHAMPION-AF trial shows WATCHMAN FLX beats anticoagulants on bleeding risk
Boston Scientific says CHAMPION-AF trial shows WATCHMAN FLX beats anticoagulants on bleeding risk Boston Scientific highlighted late-breaking clinical trial results already presented at American College of Cardiology meeting, with simultaneous publication in New England Journal of Medicine. CHAMPION
04-22 19:53
BRIEF-Flagship Pioneering, Amazon Web Services Announced Strategic Collaboration
BRIEF-Flagship Pioneering, Amazon Web Services Announced Strategic Collaboration April 1 (Reuters) - Amazon.com Inc AMZN.O : FLAGSHIP PIONEERING - CO, AMAZON WEB SERVICES ANNOUNCED STRATEGIC COLLABORATION FLAGSHIP PIONEERING - COLLABORATION TO ACCELERATE DRUG DISCOVERY AND LIFE SCIENCES INNOVATION S
04-01 18:56
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis Holding AG announced that its neuroprotective candidate, Privosegtor, has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of optic neuritis (ON), a rare, sight-threatening condition. This follows a Breakthrough Therapy designation from the U.S. FDA in January 2026, highlighting the potential of Privosegtor as the first neuroprotective therapy for ON. The designation is supported ...
03-31 08:00
Boston Scientific Drops Despite Encouraging Trial Readouts
Boston Scientific shares fall after WATCHMAN FLX and EKOS trial updates, as analysts adjust ratings and price targets despite positive data.
03-31 00:44
波士顿科学(BSX)股票3月30日收盘下跌9.06%：关键驱动因素揭晓
• 分析师因担心增长放缓而下调该股评级。 • 该公司2026年的增长预测低于市场普遍预期。 • 法律风险和参差不齐的临床数据影响了股价表现。
03-30 20:16
